This paper reviews the considerable progress in the last ten years in our understanding of the regulation of gastric secretion. The stomacl secretes acid and intrinsic factor from the parietal cells, pepsinogen from the zymogen cells, alkali from the pyloric cells, and mucus. In most situations acid, intrinsic factor and pepsinogen are secreted in parallel, and, for simplicity, only acid is considered here.
We still use the old, simple classification of cephalic, gastric and intestinal phases of gastric secretion, but we now appreciate that these three phases not only overlap in time but are also interconnected in a complex neuro-endocrine system. Many separate mechanisms have been demonstrated and are listed below, even if not all of them necessarily occur physiologically in man (see Fig 1) . Eating causes a neuro-endocrine secretion of gastric acid and pepsinogen (activated to pepsin by acid). The acidified and partly digested meal reaching the antrum and duodenum is partly neutralized by the alkaline non-parietal secretion of the pyloric gland area. Here it also inhibits fturther acid secretion, both by inhibition of gastrin release and by the neuro-endocrine release of secretin, CCK-PZ and 'enterogastrone', all of which both inhibit further acid secretion and cause further neutralization and alkalinization of the meal by pancreatic and biliary secretions, thus allowing optimum conditions for further integrated digestion.
Gastric Secretion in Peptic Ulcer Duodenal ulcer (DU): Patients with DU secrete almost twice as much acid as normal subjects, both under basal conditions and in response to stimuli such as test meals, caffeine, sub-maximal and maximal histamine, Histalog and pentagastrin. About one-third to one-half of the patients with DU respond to maximum stimuli with peak acid outputs above the upper limit of normal. About one-quarter to one-third of control subjects have peak acid outputs below the least value of peak acid output found in patients with DU: this threshold is about 15 mEq/h. This functional situation and hypersecretory discrimination corresponds with the morphological situation. Tests have been carried out in which the parietal cell mass, the number of parietal cells counted post mortem in the stomachs of patients with DU, was almost double normal, with a threshold parietal cell count (I x 109) below which DU was not seen, whereas half the stomachs of control subjects had parietal cell counts below this number. However half the patients with DU have parietal cell mass in the (upper half of the) normal range. These patients may have a greater than normal 'drive' on their parietal cells as indicated by a higher ratio of basal to peak acid output, or of insulin to pentagastrin-stimulated peak acid output. Gastric ulcer (GU): As a whole patients with GU have normal basal and peak acid outputs, corresponding to the normal number of parietal cells in their stomachs. However, GUs Four simple yardsticks can be used in assessing the value of medical treatment for peptic ulcer: remission of symptoms, demonstration of ulcer healing, clinical evidence of relapse and the occurrence of complications. The rates of clinical relapse and remission of symptoms are subjective guides and so are clearly open to observer bias. It is important, therefore, that when these standards are used the clinical observer should not be aware of which patients are receiving the test and which the control treatment. Complication rates of bleeding and perforation are simple and obvious measures but, at least in the United Kingdom, these manifestations are too infrequent to be useful in comparing different treatments.
Radiological assessment of ulcer healing, preferably by a radiologist who does not know the treatments in use, offers a good objective measure of response to treatment for gastric ulcer, but the radiological assessment of healing of duodenal ulcer is impeded by the difficulties of distinguishing scarring from active ulceration.
Gastric Ulcer
Carbenoxolone sodium is now a well proven drug for gastric ulcer (Doll et al. 1962 , Doll et al. 1965 , Horwich & Galloway 1965 , Bank et al. 1967 . Its use is often complicated by fluid retention; this tends to be dose-related as is the rate of ulcer healing (Doll et al. 1968) . Prompt treatment with thiazide diuretics together with a potassium supplement will reverse the fluid retention, the potassium supplement being particularly important because carbenoxolone occasionally, and thiazides frequently, cause hypokalbmia. Spironolactone, the only other drug which has been used to prevent fluid retention, curiously blocks both this and ulcer healing (Doll et al. 1968) . Treatment would be considerably simplified by a liquorice derivative without side-effects and three trials have so far been described using a preparation from which almost all the glycyrrhizinic acid (the fraction from which carbenoxolone is synthesized) has been removed. (Russell & Dickie 1968 , Tewari & Trembalowicz 1968 , Turpie et al. 1968 . These suggest that the preparation (Caved-S) may be as effective as carbenoxolone but free from side-effects of fluid retention. In two of these trials the number of patients given Caved-S was very small and the total number so treated in all these trials combined (30) needs increasing before the treatment can be confidently recommended. There is also evidence, which again needs confirmation, that an antipeptic agent (Amylopectin sulphate) will considerably accelerate ulcer healing (Zimmon et a!. 1969). Relapse of symptoms of gastric ulcer is common, but so far no treatment has been clearly shown to reduce the relapse rate, which is probably similar in those patients given carbenoxolone and in those whose ulcers heal following simple management by bed rest and stopping smoking.
Duodenal Ulcer
Because of the problems of radiological assessment the analysis of the results of duodenal ulcer treatment has substantially depended upon comparing symptomatic responses. The difficulties inherent in such trials are illustrated by the repeated attempts which have been made to measure the effects of anticholinergic drugs. Modem preparations, which tend to be quaternary ammonium compounds, have been claimed to have a more selective anti-secretory effect than atropine, but the evidence that they are clinically useful is by no means convincing. Synthetic anticholinergic drugs have been claimed to produce better symptomatic responses than atropine or placebo tablets (Ruffin & Cayer 1962) , and tricyclamol and glycopyrronium have been claimed to reduce the chances of ulcer relapse and complications respectively (Sun 1962 (Sun , 1964 . By contrast a marginally better initial symptomatic response obtained with methantheline compared with a placebo was not maintained later (Friedlander 1954) and further trials conducted with glycopyrronium, and glycopyrronium or hyoscyamine in maximal doses, respectively showed no difference in the incidence of relapse, or the rate of symptomatic improvement when compared with the responses to dummy tablets (Trevino et al. 1967 , Kaye et al. 1970 ; results which are in accord with others obtained using synthetic anticholinergic com-
